CVS Group PLC — LSE:CVSG closed 0.77% higher on14 September 2026, with the shares at 1,305.00p after a gain of 10.00p on the day.
Hikma Pharmaceuticals PLC — LSE:HIK closed 1.50% higher on14 September 2026, with the shares at 1,554.00p after a gain of 23.00p on the day.
Provexis plc is back on the radar afterLSE:PXS gained 14.29% on 14 September 2026, putting the small-cap healthcare company among the notable percentage movers in the London market.
ImmuPharma plc has become a notable small-cap healthcare stock afterLSE:IMM rose 13.75% on 14 September 2026.
Verici Dx is attracting attention because its investment story is shifting from scientific development towardcommercial execution. That distinction is important for a small-cap healthcare company: investors are increasingly looking for evidence that validated technology can be converted into repeat testing revenue, wider clinical adoption …
Thalia Therapeutics has become a very different company from the business investors knew under its previous identity.
Health systems on both sides of the Atlantic are under sustained pressure to do more with constrained budgets, and technology is central to how they respond. In the United States, hospitals are focused on revenue integrity, cost recovery and the economics of drug pricing; …
The FTSE 250 spans structurally growing manufacturers, specialty financial businesses and frontier-technology companies. These respond to very different forces — building regulation and theDemandfor cleaner indoor air, insurance-pricing cycles, and the adoption of new scientific tools — making theindexa way to assemble genuinely diversified …
The FTSE 250 rewards investors willing to look beyond the mega-caps for businesses with clearer, more specific stories. Consumer-facing retailers and life-sciences companies both feature prominently in the index, and together they capture two of the defining forces in the UKEquitymarket: the health of …
CT Healthcare Trust is attracting attention because the stock is moving lower even though its underlying portfolio has demonstrated relative resilience against a difficult global healthcare backdrop.